Impact Blogs
AstraZeneca, the UK-based pharmaceutical giant, reaffirmed its commitment to patient safety amid concerns about potential rare side effects of its COVID-19 vaccine. The company spokesperson stated, 'Our sympathy goes out to anyone who has lost loved ones or reported health problems.'
Source: businesstoday.in
Photo by National Cancer Institute on Unsplash
AstraZeneca admitted that its COVID-19 vaccine, sold globally as Covishield and Vaxzevria, may cause Thrombocytopenia Syndrome (TTS) in 'very rare cases'. This condition leads to blood clot formation and lowered platelet count.
Photo by Hal Gatewood on Unsplash
In the UK, AstraZeneca faces a lawsuit over claims that its vaccine led to deaths and severe injuries in several cases. Complications reported include stroke, heart failure, and leg amputations.
Photo by Tingey Injury Law Firm on Unsplash
In India, AstraZeneca's Vaxzevria vaccine is produced by Serum Institute of India (SII) and marketed as Covishield. The vaccine uses a viral vector platform instead of mRNA technology.
Photo by Raghu Nayyar on Unsplash
Covishield uses a modern chimpanzee adenovirus to transport the COVID-19 spike protein into human cells. While this virus cannot infect the vaccine recipient, it can effectively teach the immune system to defend against similar viruses.
In 2023, the World Health Organisation (WHO) reported that TTS was a new adverse event after COVID-19 vaccination in individuals using non-replicant adenovirus vector-based vaccines. The WHO issued guidance to increase awareness about TTS.
Photo by Martin Sanchez on Unsplash